You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
Latest Byetta Articles
Popular Byetta Articles
Highly Recommended Byetta Articles
Send a link to this page to your friends and colleagues.
The FDA has announced that starting in early April, its Endocrinologic and Metabolic Drugs Advisory Committee will begin looking into two new drugs for type 2 diabetes: saxagliptin tablets from Bristol-Meyers Squibb and liraglutide, an injection drug from Novo Nordisk.
Both drugs are designed to lower blood glucose levels in people with type 2 diabetes, but there are concerns that they may be linked to a higher occurrence of cardiovascular problems in diabetes patients. Consequently, the committee will focus on whether either treatment increases patients' risk of heart attacks or strokes.
Neither drug is a totally new therapy. Saxagliptin is similar to Merck's Januvia, a DPP-4 inhibitor that works by increasing the body's level of incretin hormones, which lowers blood glucose.
Liraglutide, like Amylin Pharmaceuticals' and Eli Lilly & Co.'s Byetta, is a long-acting form of the hormone GLP-1, which triggers the release of insulin. Unlike Byetta, which is injected twice daily, liraglutide will be marketed as a once-daily injection.
(Amylin and Lilly currently are testing a long-term form of Byetta that would be injected once a week. Timed-release capsules in the injection dissolve at specific intervals to deliver a continuous supply of the drug to the patient.)
The FDA's desire to scrutinize saxagliptin and liraglutide comes from its December 2008 directive calling for all new diabetes drug treatments to demonstrate that they do not increase cardiovascular risks.
Among the new testing conditions requested by the agency is the inclusion of older, sicker diabetes patients who are at higher risk of having a heart attack or stroke. Additionally, it is asking that drug studies follow patients for up to two years, versus the current three to six months.
Because both drugs were submitted to the FDA before issuance of the new December guidelines, there is some question about whether the agency will request more clinical data from the manufacturers.
1 comment - Mar 24, 2009
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.